Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 14 February, 2020

FIL Limited

Form 8.3 - Abbvie Inc

RNS Number : 1036D
FIL Limited
14 February 2020
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

FMR LLC and/or one or more of its direct or indirect subsidiaries

And

FIL Limited and/or one or more of its direct and indirect subsidiaries

Company dealt in

ABBVIE INC

Class of relevant security to which the dealings being disclosed relate 2)

ORDINARY SHARES

Date of dealing

13-February-2020

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)


Long

Short


Number


(%)

Number


(%)

(1) Relevant securities

40,115,325                 2.71%


(2) Derivatives (other than options)



(3) Options and agreements to purchase/sell



Total

40,115,325                 2.71%


                                                                                     

THE ABOVE INCLUDES A TRANSFER OUT OF 167 ORDINARY SHARES

                                                                                 

 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short


Number


(%)

Number


(%)

(1) Relevant securities



 

(2) Derivatives (other than options)



 

(3) Options and agreements to purchase/sell



Total




Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Purchase

18,000

95.32 USD/Share

Purchase

7,171

95.36 USD/Share

Purchase

1,000

95.37 USD/Share

Purchase

400

95.38USD/Share

Purchase

15,000

95.40 USD/Share

Purchase

11,169

95.46 USD/Share

Purchase

3,021

95.60 USD/Share

Purchase

3,139

95.62 USD/Share

Purchase

641

96.30. USD/Share

Purchase

800

96.37 USD/Share

Purchase

10,939

96.47 USD/Share

Purchase

1,100

96.49 USD/Share

Purchase

3,748

96.50 USD/Share

Purchase

17,513

96.51 USD/Share

Purchase

3,600

96.55 USD/Share

Purchase

707

96.78 USD/Share

Purchase

1,400

96.80 USD/Share

Purchase

600

96.94 USD/Share

Purchase

10,431

96.98 USD/Share

Purchase

4,962

97.09 USD/Share

Purchase

2,463

96.85USD/Share

Sale

4,948

95.86 USD/Share

Sale

800

95.97 USD/Share

Sale

1,260

95.99 USD/Share

Sale

100

96.00 USD/Share

Sale

4,476

96.01 USD/Share

Sale

616

96.02 USD/Share

Sale

200

96.03 USD/Share

Sale

641

96.30 USD/Share

Sale

178

96.33 USD/Share

Sale

459

96.36 USD/Share

Sale

24

97.06 USD/Share

Sale

362

96.69 USD/Share

Sale

4

96.29 USD/Share

Sale

6

96.75 USD/Share

Sale

7

97.05 USD/Share

Sale

8

97.00 USD/Share

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)





 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)








 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit 5)




 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)




Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            NO

 

Date of disclosure

14-February-2020

Contact name

Kevin Petley

Telephone number

00 353 1 223 1447

a connected EFM, name of offeree/offeror with which connected


If a connected EFM, state nature of connection (Note 10)


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEKKQBNQBKDCBD

a d v e r t i s e m e n t